Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. (October 2012)

• Record Type: Journal Article
• Authors: Jiang, Yiling; Gauthier, Aline; Annemans, Lieven; van der Linden, Mark; Nicolas-Spony, Laurence; Bresse, Xavier
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 12:Number 5(2012)
• Page Start: 645
• Page End: 660
• Publication Date: 2012-10
• Subjects: cost–effectiveness analysis -- epidemiological changes -- invasive pneumococcal diseases -- pneumococcal pneumonia -- polysaccharide pneumococcal vaccine; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1586/erp.12.54
• Languages: English
• ISSNs: 1473-7167

Abstract

The introduction of routine infant vaccination against pneumococcal disease has resulted in a decreased overall invasive pneumococcal disease incidence in adults but also a change in invasive pneumococcal disease serotypes. This study aimed to assess the cost–effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany in this context. A population-based Markov model was developed. A cohort of adults currently eligible for vaccination was followed until death. Adult vaccination with PPV23 was associated with an incremental cost–effectiveness ratio of €17, 065/quality-adjusted life years gained from the third-party payer's perspective. Univariate sensitivity analyses showed that the incremental cost–effectiveness ratio was below €50, 000/quality-adjusted life years gained in most test scenarios. The model suggests that adult PPV23 vaccination is cost effective in Germany, due to its broad serotype coverage. This is despite epidemiological changes in Streptococcus pneumoniae serotypes caused by wider use of pneumococcal conjugate vaccines during childhood.